GlassScriptPhysician profile
Rosario Davidson
NPI 1972778785
$4,703.72
in general payments reported to CMS, 2019-2025
34 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $734 · 2022: $1,112 · 2023: $960 · 2024: $862 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $702.43 | 2021-2025 | Breztri, Farxiga, Lokelma |
| Lilly USA, LLC | $635.90 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $434.11 | 2021-2024 | |
| Novo Nordisk INC | $345.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $332.99 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $277.47 | 2021-2025 | |
| Abbott Laboratories | $195.31 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.77 | 2021-2025 | Jardiance |
| Amgen INC. | $158.84 | 2024-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.04 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $131.27 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Scilex Pharmaceuticals INC. | $125.41 | 2022-2024 | Ztlido |
| Pfizer INC. | $121.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $114.20 | 2022-2025 | |
| Corcept Therapeutics | $101.75 | 2025 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $90.48 | 2021-2023 | Injectafer |
| Glaxosmithkline, LLC. | $71.51 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $60.07 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $59.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $58.70 | 2024-2025 | Voquezna |
| Bausch Health US, LLC | $53.98 | 2025 | Aplenzin |
| Astellas Pharma US INC | $53.05 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.12 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $47.13 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $32.82 | 2023-2024 | Rexulti |
| Depuy Synthes Sales INC. | $23.29 | 2024 | Orthovisc |
| Otsuka America Pharmaceutical, INC. | $16.73 | 2024 | Rexulti |
| Nevro Corp. | $16.34 | 2023 | Senza |
| Ironwood Pharmaceuticals, INC | $16.11 | 2024 | |
| Gilead Sciences, INC. | $15.83 | 2025 | |
| Optinose US, INC. | $14.36 | 2021 | |
| Genentech USA, INC. | $14.29 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.21 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.61 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosario Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.